Diagnosis and treatment of mood disorders that co-occur with schizophrenia

Psychiatric Services

Volumn 52, Issue 7, 2001, Pages 911-919

  Escamilla, M A ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CLOZAPINE; IMIPRAMINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

AFFECTIVE NEUROSIS; ARTICLE; COMORBIDITY; DEPRESSION; DISEASE CLASSIFICATION; MANIA; PSYCHOTHERAPY; SCHIZOPHRENIA; SYMPTOMATOLOGY;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; MOOD DISORDERS; RANDOMIZED CONTROLLED TRIALS; SCHIZOPHRENIA;

EID: 0034937816     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.52.7.911     Document Type: Article

References (65)

1. Strategies to reduce misdiagnosis of bipolar depression
2. Treatment of schizoaffective disorder and schizophrenia with mood symptoms
3. Neural mechanisms of emotion
4. The structure of psychosis: Latent class analysis of probands from the roscommon family study
5. Are schizophrenia and bipolar disorders related? A review of family and molecular studies
6. A re-appraisal of faculty psychology
7. Discussion on the diagnosis and treatment of the milder forms of the manic depressive psychosis
8. The acute schizoaffective psychoses
9. Diagnostic criteria for use in psychiatric research
10. Postpsychotic depression in schizophrenia
11. Long-term outcome of major psychoses. II: Schizoaffective disorder compared with schizophrenia, affective disorders, and a surgical control group
12. Toward the validation of RDC schizoaffective disorder
13. A prospective longitudinal 10-year study of schizophrenia's three major factors and depression
14. Pyramidical model of schizophrenia
15. Two-tier diagnosing in psychiatry
16. Schizophrenia and the question of genetic heterogeneity
17. Outcome predictors in acute schizophrenia: Prospective significance of background and clinical dimensions
18. The Chestnut Lodge follow-up study: II. Long-term outcome of schizophrenia and the affective disorders
19. Schizoaffective mania reconsidered
20. Ten-year outcome: Patients with schizoaffective disorders, schizophrenia, affective disorders, and mood-incongruent psychotic symptoms
21. Diagnostic accuracy and confusability analyses: An application to the diagnostic interview for genetic studies
22. Suicidal behavior in hospitalized schizophrenics
23. The efficacy of atyical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia
24. Mood disorders in schizophrenia: Epidemiology and comorbidity
25. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the national comorbidity survey
26. Frequency and differential diagnosis of depressive syndromes in schizophrenia
27. Depression, affect, and negative symptoms in schizophrenia
28. Treatment of negative symptoms
29. Mood disorders and schizophrenia
30. Biology and etiology of affective disorders in schizophrenia
31. Differentiation of depression, negative symptoms, and EPS in schizophrenia
32. Effects of psychotherapy in schizophrenia. II: Comparative outcome of two forms of treatment
33. Group therapy with schizophrenics: A review of controlled studies
34. Effect of nonpharmacologic interventions on outcome
35. Antidepressants in "depressed" schizophrenic inpatients: A controlled trial
36. Thioridazine improves affective symptoms in schizophrenic patients
37. Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome
38. Adjunctive imipramine in the treatment of postpsychotic depression
39. Maintenance imipramine therapy for secondary depression in schizophrenia
40. The anticholinergic intoxication syndrome: Diagnosis and treatment
41. Long-term treatment of mood disorders in schizophrenia
42. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment
43. Clozapine reduces violence and persistent aggression in schizophrenia
44. An overview of olanzapine safety
45. Valproic acid amide as a prophylactic agent in affective and schizoaffective disorders
46. Clozapine therapy in refractory affective disorders: Polarity predicts response in long-term follow-up
47. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia
48. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders